Veracyte has successfully shifted from a high-investment growth phase to sustained profitability, reporting positive adjusted EBITDA for the last two consecutive quarters. The company’s self-fortifying balance sheet now holds over $300 million in cash and short-term investments, making it largely debt-free. This financial flexibility supports ongoing R&D and commercial initiatives without external financing, reducing dilution risk for shareholders and enhancing operating leverage as volume scales.

Management projects 16% top-line growth in fiscal 2025, targeting $515–$517 million in revenue, driven by deeper penetration in the prostate cancer market, anticipated entry into minimal residual disease testing later in the year, and the U.S. re-launch of its Prosigna breast cancer test. With these initiatives, Veracyte forecasts an adjusted EBITDA margin north of 25%, underscoring its ability to maintain profitable execution even as it invests in new indications.

At the recent J.P. Morgan Healthcare Conference, CEO Marc Stapley outlined Veracyte’s platform approach, which leverages whole transcriptome and whole genome assays to generate rich datasets beyond immediate clinical questions. This ‘data-driven flywheel’ is designed to accelerate evidence generation, expand clinical utility across additional cancer types and geographies, and drive greater physician adoption. The company plans to extend this platform into Europe and Asia-Pacific markets over the next 12–18 months.